Literature DB >> 10688809

Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda.

Z J Bulaj1, J D Phillips, R S Ajioka, M R Franklin, L M Griffen, D J Guinee, C Q Edwards, J P Kushner.   

Abstract

Inherited and acquired factors have been implicated in the pathogenesis of porphyria cutanea tarda (PCT), a disorder characterized by a photosensitive dermatosis and hepatic siderosis. This study, comprising 108 patients with PCT, was intended to define the role of hemochromatosis gene (HFE) mutations in the expression of PCT and to determine the contribution of acquired factors including alcohol, hepatitis C virus (HCV), and estrogen. The 2 known HFE mutations, cysteine 282 tyrosine (Cys282Tyr) and histidine 63 asparagine (His63Asp), were detected by polymerase chain reaction, and anti-HCV immunoglobulin G was detected serologically. Liver biopsies were graded for iron content, inflammation, and fibrosis. Estimates of alcohol and estrogen use were based on a questionnaire. Of the PCT patients tested, 19% were homozygous for the Cys282Tyr mutation; controls were equal to 0.5%. The compound heterozygous genotype was detected in 7% of the PCT patients; controls were less than 1%. The transferrin saturation, serum ferritin, and liver iron burden of all PCT patients were higher than those of nonporphyric controls. The highest values were found in PCT patients homozygous for the Cys282Tyr mutation. Of the patients studied, 59% were HCV positive (compared with 1.8% of the population), and 46% consumed more than 70 g of alcohol daily. Of the female patients, 63% were ingesting estrogens. Hepatic damage was most marked in patients with the Cys282Tyr/Cys282Tyr genotype who had HCV and drank heavily. Homozygosity for the Cys282Tyr mutation and HCV are the greatest risk factors for expression of PCT, and in most patients, more than 1 risk factor was identified. It was common for patients with HCV to consume alcohol. Patients with PCT should be screened for HFE mutations and for HCV. (Blood. 2000;95:1565-1571)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10688809

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  23 in total

Review 1.  Porphyrias at a glance: diagnosis and treatment.

Authors:  Maria Domenica Cappellini; Valentina Brancaleoni; Giovanna Graziadei; Dario Tavazzi; Elena Di Pierro
Journal:  Intern Emerg Med       Date:  2010-10       Impact factor: 3.397

Review 2.  Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review.

Authors:  Caterina Ferreli; Giulia Gasparini; Aurora Parodi; Emanuele Cozzani; Franco Rongioletti; Laura Atzori
Journal:  Clin Rev Allergy Immunol       Date:  2017-12       Impact factor: 8.667

3.  Down-regulation of hepcidin in porphyria cutanea tarda.

Authors:  Richard S Ajioka; John D Phillips; Robert B Weiss; Diane M Dunn; Maria W Smit; Sean C Proll; Michael G Katze; James P Kushner
Journal:  Blood       Date:  2008-09-22       Impact factor: 22.113

4.  Uroporphyria in the Cyp1a2-/- mouse.

Authors:  John D Phillips; James P Kushner; Hector A Bergonia; Michael R Franklin
Journal:  Blood Cells Mol Dis       Date:  2011-08-30       Impact factor: 3.039

5.  Hemochromatosis and transferrin receptor gene polymorphisms in chronic hepatitis C: impact on iron status, liver injury and HCV genotype.

Authors:  Sven G Gehrke; Wolfgang Stremmel; Inge Mathes; Hans-Dieter Riedel; Karin Bents; Birgit Kallinowski
Journal:  J Mol Med (Berl)       Date:  2003-10-14       Impact factor: 4.599

6.  Associations among behavior-related susceptibility factors in porphyria cutanea tarda.

Authors:  Sajid Jalil; James J Grady; Chul Lee; Karl E Anderson
Journal:  Clin Gastroenterol Hepatol       Date:  2009-11-27       Impact factor: 11.382

Review 7.  Role of alcohol in the regulation of iron metabolism.

Authors:  Duygu Dee Harrison-Findik
Journal:  World J Gastroenterol       Date:  2007-10-07       Impact factor: 5.742

Review 8.  Porphyrias in Japan: compilation of all cases reported through 2002.

Authors:  Masao Kondo; Yuzo Yano; Masuo Shirataka; Gumpei Urata; Shigeru Sassa
Journal:  Int J Hematol       Date:  2004-06       Impact factor: 2.490

Review 9.  HFE gene in primary and secondary hepatic iron overload.

Authors:  Giada Sebastiani; Ann-P Walker
Journal:  World J Gastroenterol       Date:  2007-09-21       Impact factor: 5.742

10.  Primary hemochromatosis presented by porphyria cutanea tarda: a case report.

Authors:  H Jorn Bovenschen; Wynand H P M Vissers
Journal:  Cases J       Date:  2009-06-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.